Pasar al contenido principal

INTERACCION AUTOFAGIA-INFLAMASOMA COMO DIANA TERAPEUTICA EN LA ENFERMEDAD DE ALZHEIMER

RTI2018-095572-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease

  • Gregorio, Estefanía de
  • Colell Riera, Anna
  • Morales, Albert
  • Marí, Montserrat
Inflammation is an adaptive response in pursuit of homeostasis reestablishment triggered by harmful conditions or stimuli, such as an infection or tissue damage. Liver diseases cause approximately 2 million deaths per year worldwide and hepatic inflammation is a common factor to all of them, being the main driver of hepatic tissue damage and causing progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH), cirrhosis and, ultimately, hepatocellular carcinoma (HCC). The metabolic sensor SIRT1, a class III histone deacetylase with strong expression in metabolic tissues such as the liver, and transcription factor NF-κB, a master regulator of inflammatory response, show an antagonistic relationship in controlling inflammation. For this reason, SIRT1 targeting is emerging as a potential strategy to improve different metabolic and/or inflammatory pathologies. In this review, we explore diverse upstream regulators and some natural/synthetic activators of SIRT1 as possible therapeutic treatment for liver diseases, This research was funded by Ministerio de Ciencia e Innovación (Project# RTI2018-095572-B-I00 to A.C.; Project# RTI2018-095672-B-I00 to A.M.), and by Instituto de Salud Carlos III (Project# PI19/01410 to M.M.) and co-funded by European Union (ERDF “A way to make Europe”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease

  • Roca-Agujetas, Vicente
  • Barbero-Camps, Elisabet
  • Dios, Cristina de
  • Podlesniy, Petar
  • Abadin, Xenia
  • Morales, Albert
  • Marí, Montserrat
  • Trullas, Ramón
  • Colell Riera, Anna
Background: Emerging evidence indicates that impaired mitophagy-mediated clearance of defective mitochondria is a critical event in Alzheimer’s disease (AD) pathogenesis. Amyloid-beta (Aβ) metabolism and the microtubule-associated protein tau have been reported to regulate key components of the mitophagy machinery. However, the mechanisms that lead to mitophagy dysfunction in AD are not fully deciphered. We have previously shown that intraneuronal cholesterol accumulation can disrupt the autophagy flux, resulting in low Aβ clearance. In this study, we examine the impact of neuronal cholesterol changes on mitochondrial removal by autophagy. Methods: Regulation of PINK1-parkin-mediated mitophagy was investigated in conditions of acute (in vitro) and chronic (in vivo) high cholesterol loading using cholesterol-enriched SH-SY5Y cells, cultured primary neurons from transgenic mice overexpressing active SREBF2 (sterol regulatory element binding factor 2), and mice of increasing age that express the amyloid precursor protein with the familial Alzheimer Swedish mutation (Mo/HuAPP695swe) and mutant presenilin 1 (PS1-dE9) together with active SREBF2. Results: In cholesterol-enriched SH-SY5Y cells and cultured primary neurons, high intracellular cholesterol levels stimulated mitochondrial PINK1 accumulation and mitophagosomes formation triggered by Aβ while impairing lysosomal-mediated clearance. Antioxidant recovery of cholesterol-induced mitochondrial glutathione (GSH) depletion prevented mitophagosomes formation indicating mitochondrial ROS involvement. Interestingly, when brain cholesterol accumulated chronically in aged APP-PSEN1-SREBF2 mice the mitophagy flux was affected at the early steps of the pathway, with defective recruitment of the key autophagy receptor optineurin (OPTN). Sustained cholesterol-induced alterations in APP-PSEN1-SREBF2 mice promoted an age-dependent accumulation of OPTN into HDAC6-positive aggresomes, which disappeared after in vivo treatment with GSH ethyl ester (GSHee). The analyses in post-mortem brain tissues from individuals with AD confirmed these findings, showing OPTN in aggresome-like structures that correlated with high mitochondrial cholesterol levels in late AD stages. Conclusions: Our data demonstrate that accumulation of intracellular cholesterol reduces the clearance of defective mitochondria and suggest recovery of the cholesterol homeostasis and the mitochondrial scavenging of ROS as potential therapeutic targets for AD., This work was supported by the Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) under grants: RTI2018–095572-B-100 to A.C., RTI2018–095672-B-I00 to A.M., SAF2017–89791-R to R.T.; Fundació La Marató de TV3 (2014–0930 to A.C.); the Instituto de Salud Carlos III under grant PI19/01410 to M.M.; the Agencia de Gestió d’Ajuts Universitaris i de Recerca, Spain (2017_SGR_177); and the CERCA Programme from the Generalitat de Catalunya, Spain. C.dD. has a FPU fellowship from Ministerio de Ciencia, Innovación y Universidades, Spain. We acknowledge support of the publication fee by the CSIC Open Acess Publication Support Initiative through its Unit of Information Resource for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Upregulation of brain cholesterol levels inhibits mitophagy in Alzheimer disease

  • Roca-Agujetas, Vicente
  • Dios, Cristina de
  • Abadin, Xenia
  • Colell Riera, Anna
Mitochondrial dysfunction is behind several neurodegenerative diseases, including Alzheimer disease (AD). Accumulation of damaged mitochondria is already observed at the early stages of AD and has been linked to impaired mitophagy, but the mechanisms underlying this alteration are still not fully known. In our recent study, we show that intracellular cholesterol enrichment can downregulate amyloid beta (Aβ)-induced mitophagy. Mitochondrial glutathione depletion resulting from high cholesterol levels promotes PINK1 (PTEN induced kinase 1)-mediated mitophagosome formation; however, mitophagy flux is ultimately disrupted, most likely due to fusion deficiency of endosomes-lysosomes caused by cholesterol. Meanwhile, in APP-PSEN1-SREBF2 mice, an AD mouse model that overexpresses the cholesterol-related transcription factor SREBF2, cholesterol accumulation prompts an oxidative- and age-dependent cytosolic aggregation of the mitophagy adaptor OPTN (optineurin), which prevents mitophagosome formation despite enhanced PINK1-PRKN/parkin signaling. Hippocampal neurons from postmortem brain of AD individuals reproduce the progressive accumulation of OPTN in aggresome-like structures accompanied by high levels of mitochondrial cholesterol in advanced stages of the disease. Overall, these data provide new insights into the impairment of the PINK1-PRKN mitophagy pathway in AD and suggest the combination of mitophagy inducers with strategies focused on restoring the cholesterol homeostasis and mitochondrial redox balance as a potential disease-modifying therapy for AD., This work was supported by the Fundació la Marató de TV3 [2014-093]; Ministerio de Ciencia, Innovación y Universidades (ES) [RTI2018- 095572-B-100]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species

  • Cucarull, Blanca
  • Tutusaus, Anna
  • Hernáez-Alsina, Tania
  • García de Frutos, Pablo
  • Reig, Maria
  • Colell Riera, Anna
  • Marí, Montserrat
  • Morales, Albert
Sorafenib and regorafenib, multikinase inhibitors (MKIs) used as standard chemotherapeutic agents for hepatocellular carcinoma (HCC), generate reactive oxygen species (ROS) during cancer treatment. Antioxidant supplements are becoming popular additions to our diet, particularly glutathione derivatives and mitochondrial-directed compounds. To address their possible interference during HCC chemotherapy, we analyzed the effect of common antioxidants using hepatoma cell lines and tumor spheroids. In liver cancer cell lines, sorafenib and regorafenib induced mitochondrial ROS production and potent cell death after glutathione depletion. In contrast, cabozantinib only exhibited oxidative cell death in specific HCC cell lines. After sorafenib and regorafenib administration, antioxidants such as glutathione methyl ester and the superoxide scavenger MnTBAP decreased cell death and ROS production, precluding the MKI activity against hepatoma cells. Interestingly, sorafenib-induced mitochondrial damage caused PINK/Parkin-dependent mitophagy stimulation, altered by increased ROS production. Finally, in sorafenib-treated tumor spheroids, while ROS induction reduced tumor growth, antioxidant treatments favored tumor development. In conclusion, the anti-tumor activity of specific MKIs, such as regorafenib and sorafenib, is altered by the cellular redox status, suggesting that uncontrolled antioxidant intake during HCC treatment should be avoided or only endorsed to diminish chemotherapy-induced side effects, always under medical scrutiny., Study funded by grants from Instituto de Salud Carlos III (PI19/01410 to M.M., and PI19/00358 to M.R.), CIBEREHD and CIBERNED; Ministerio de Ciencia, Innovación y Universidades (RTI2018-095672-B-I00 to A.M. and P.G.F., and RTI2018-095572-B-100 to A.C.) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); AGAUR (2017_SGR_177 to A.M.) and CERCA Programme/Generalitat de Catalunya
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances

  • Cucarull, Blanca
  • Tutusaus, Anna
  • Rider, Patricia
  • Hernáez-Alsina, Tania
  • Cuño-Gómiz, Carlos
  • García de Frutos, Pablo
  • Colell Riera, Anna
  • Marí, Montserrat
  • Morales, Albert
Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to be a serious medical problem with poor prognosis, without major therapeutic improvement for years and increasing incidence. Fortunately, advances in systemic treatment options are finally arriving for HCC patients. After a decade of sorafenib as a standard therapy for advanced HCC, several tyrosine kinase inhibitors (TKIs), antiangiogenic antibodies, and immune checkpoint inhibitors have reached the clinic. Although infections by hepatitis B virus and hepatitis C virus remain principal factors for HCC development, the rise of non-alcoholic steatohepatitis from diabetes mellitus or metabolic syndrome is impeding HCC decline. Knowledge of specific molecular mechanisms, based on the etiology and the HCC microenvironment that influence tumor growth and immune control, will be crucial for physician decision-making among a variety of drugs to prescribe. In addition, markers of treatment efficacy are needed to speed the movement of patients towards other potentially effective treatments. Consequently, research to provide scientific data for the evidence-based management of liver cancer is guaranteed in the coming years and discussed here., This research was funded by Instituto de Salud Carlos III, grant number PI19/01410 to M.M.; CIBEREHD and CIBERNED; Ministerio de Ciencia e Innovación, grant numbers RTI2018- 095672-B-I00 to A.M. and P.G.F. and RTI2018-095572-B-100 to A.C.; and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); Ayuda Extraordinaria CSIC 2021AEP095 to A.M. and P.G.F., AGAUR, grant number 2017_SGR_177 to A.M.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Enhanced oxidative stress-regulated by cholesterol promotes necroptosis in Alzheimer's disease

  • Abadin, Xenia
  • Dios, Cristina de
  • Roca-Agujetas, Vicente
  • Puigros Serra, Margalida
  • Claderón, Anna
  • Trullas, Ramón
  • Colell Riera, Anna
Trabajo presentado en el Global summit on Neurodegeneratice Disease Neuro, celebrado en Salamanca (España), del 21 al 24 de junio de 2022, How do neurons die in Alzheimer¿s disease (AD)? The answer is not clear. Caspases, primary effectors during apoptosis, are activated in AD brains; however, apoptotic morphology is not evident. Furthermore, the progress of the disease that lasts for decades seems incompatible with an apoptotic death program. A recent study offers compelling evidence of active necroptosis, a regulated inflammatory cell death, in post-mortem AD brains, but still, the events that trigger or regulate necroptosis in AD are not fully known. It has been reported that oxidative stress may be determinant as to whether a cell initiates necroptosis; it is, therefore, likely that mitochondrial dysfunction, observed in the early stages of AD, might favor cells to undergo necroptosis. Previous studies from our group have shown that high intracellular cholesterol levels deplete the mitochondrial pool of GSH, thus sensitizing neurons against amyloid-beta (A¿)-induced mitochondrial oxidative stress. The present study is aimed to evaluate whether cholesterol can regulate the necroptotic pathway using both APP-PSEN1 mice that overexpress SREBF2 and cholesterol-enriched SH-SY5Y cells. Methods: Cholesterol enrichment was assessed by incubating the cells with soluble cholesterol:methyl-cyclodextrin complex (50 ¿g/ml) for 1 h followed by 4 h recovery. To induce necroptosis, cells were treated for 24 h with TLQ [TNF¿ (10 ng/ml) plus the SMAC mimetic (LCL-161, 10 ¿M) and the pan-caspase inhibitor qVD-OPH (10 ¿M)]. Results: In the brains of APP-PSEN1-SREBF2 mice, we found an up-regulated expression of the necroptosis-related proteins RIPK3 and MLKL, which together with RIPK1 accumulated in the urea-soluble protein fraction, indicative of necrosome assembly. Moreover, western blot analyses of brain extracts from triple transgenic mice also showed high levels of c-FLIP, the natural inhibitor of caspase-8, further pointing to a cholesterol-regulated engagement of the necroptotic pathway. In SH-SY5Y cells, cholesterol enrichment resulted in enhanced cell death after exposure to TLQ, which was prevented by RIPK1 and RIPK3 inhibitors (Necrostatin and GSK¿872, respectively). Similar protection against TLQ-induced necroptosis was achieved when mitochondrial GSH levels were recovered by GSH ethyl ester. Intriguingly, cholesterol also regulated the intracellular localization of RIPK3 and MLKL. Confocal microscopy showed an increased presence of nuclear RIPK3 and MLKL in cholesterol-enriched cells, recently described as a requirement for the subsequent necrosome formation in the cytosol. Overall, these findings indicate that high intracellular cholesterol levels compromise neuronal viability, promoting necroptosis and subsequent necroptosis, a pro-inflammatory type of cell death, which ultimately may contribute to chronic neuroinflammation in AD., Proyectos RTI2018-095572-B-100 y PID2020-115091RB-I00 financiados por MCIN/AEI /10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Enhanced oxidative stress regulated by cholesterol promotes Necroptosis in Alzheimer's disease

  • Abadin, Xenia
  • Dios, Cristina de
  • Roca-Agujetas, Vicente
  • Ivars, Elia
  • Puigros Serra, Margalida
  • Calderón, Anna
  • Trullas, Ramón
  • Colell Riera, Anna
Trabajo presentado en la Alzheimer's Association International Conference (AAIC), celebrada en Philadelphia (Estados Unidos), del 28 de julio al 1 de agosto de 2023, Background: Necroptosis has been reported in post-mortem Alzheimer’s disease (AD) brains, but still, the events that trigger or regulate this type of inflammatory cell death in AD are not fully known. Oxidative stress may be determinant as to whether a cell initiates necroptosis; Therefore, it is, likely that mitochondrial dysfunction, observed in the early stages of AD, might favor cells to undergo necroptosis. Previous studies from our group have shown that high intracellular cholesterol levels deplete the mitochondrial pool of GSH, thus sensitizing neurons against amyloid-beta (Ab)-induced mitochondrial oxidative stress. The present study is aimed to evaluate whether cholesterol can regulate the necroptotic pathway using both APP-PSEN1 mice that overexpress the cholesterol-related transcription factor SREBF2 and cholesterol-enriched SH-SY5Y cells. Method: Cholesterol enrichment was assessed by incubating the cells with soluble cholesterol:methyl-cyclodextrin complex (50 mg/ml) for 1 h followed by 4 h recovery. To induce necroptosis, cells were treated with TLQ [TNFa (10 ng/ml) plus the SMAC mimetic (LCL-161, 10 mM) and the pan-caspase inhibitor qVD-OPH (10 mM)] for 24 h. Results: Brains from APP-PSEN1-SREBF2 mice show up-regulated expression of the necroptosis-related proteins RIPK3 and MLKL, which together with RIPK1 accumulated in the urea-soluble protein fraction, indicative of necrosome assembly. Moreover, western blot analyses of brain extracts from triple transgenic mice also showed high levels of c-FLIP, the natural inhibitor of caspase-8, further pointing to a cholesterol-regulated engagement of the necroptotic pathway. In SH-SY5Y cells, cholesterol enrichment resulted in enhanced cell death after exposure to TLQ, which was prevented by RIPK1 and RIPK3 inhibitors (Necrostatin and GSK’872, respectively). Similar protection against TLQ-induced necroptosis was achieved when mitochondrial GSH levels were recovered by GSH ethyl ester. Intriguingly, cholesterol also regulated the intracellular localization of RIPK3 and MLKL. Confocal microscopy showed an increased presence of nuclear RIPK3 and MLKL in cholesterol-enriched cells, recently described as a requirement for the subsequent necrosome formation in the cytosol. Conclusion: Overall, these findings indicate that high intracellular cholesterol levels compromise neuronal viability, promoting oxidative stress and subsequent necroptosis, a pro-inflammatory type of cell death, which ultimately may contribute to chronic neuroinflammation in AD., This work was supported by grants from Ministerio de Ciencia y Innovación (RTI 2018 095572 B 100 and PID 2020 115091 RB 100 AGAUR (SGR 00490 and 2021 FI_B 00627
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis

  • Dios, Cristina de
  • Abadin, Xenia
  • Roca-Agujetas, Vicente
  • Jiménez Martínez, Marina
  • Morales, Albert
  • Trullas, Ramón
  • Marí, Montserrat
  • Colell Riera, Anna
Background: Persistent inflammatory response in the brain can lead to tissue damage and neurodegeneration. In Alzheimer's disease (AD), there is an aberrant activation of inflammasomes, molecular platforms that drive inflammation through caspase-1-mediated proteolytic cleavage of proinflammatory cytokines and gasdermin D (GSDMD), the executor of pyroptosis. However, the mechanisms underlying the sustained activation of inflammasomes in AD are largely unknown. We have previously shown that high brain cholesterol levels promote amyloid-β (Aβ) accumulation and oxidative stress. Here, we investigate whether these cholesterol-mediated changes may regulate the inflammasome pathway. Methods: SIM-A9 microglia and SH-SY5Y neuroblastoma cells were cholesterol-enriched using a water-soluble cholesterol complex. After exposure to lipopolysaccharide (LPS) plus muramyl dipeptide or Aβ, activation of the inflammasome pathway was analyzed by immunofluorescence, ELISA and immunoblotting analysis. Fluorescently-labeled Aβ was employed to monitor changes in microglia phagocytosis. Conditioned medium was used to study how microglia-neuron interrelationship modulates the inflammasome-mediated response. Results: In activated microglia, cholesterol enrichment promoted the release of encapsulated IL-1β accompanied by a switch to a more neuroprotective phenotype, with increased phagocytic capacity and release of neurotrophic factors. In contrast, in SH-SY5Y cells, high cholesterol levels stimulated inflammasome assembly triggered by both bacterial toxins and Aβ peptides, resulting in GSDMD-mediated pyroptosis. Glutathione (GSH) ethyl ester treatment, which recovered the cholesterol-mediated depletion of mitochondrial GSH levels, significantly reduced the Aβ-induced oxidative stress in the neuronal cells, resulting in lower inflammasome activation and cell death. Furthermore, using conditioned media, we showed that neuronal pyroptosis affects the function of the cholesterol-enriched microglia, lowering its phagocytic activity and, therefore, the ability to degrade extracellular Aβ. Conclusions: Changes in intracellular cholesterol levels differentially regulate the inflammasome-mediated immune response in microglia and neuronal cells. Given the microglia-neuron cross-talk in the brain, cholesterol modulation should be considered a potential therapeutic target for AD treatment, which may help to block the aberrant and chronic inflammation observed during the disease progression., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” [Grant RTI2018–095572-B-100 (A.C.) RTI2018–095672-B-I00 (A.M.) and PID2020-115091RB-I00 (R.T)] and the Instituto de Salud Carlos III [Grant PI19/01410 (M.M.)]. C.D. was granted with a FPU fellowship (FPU15/01305) from Ministerio de Ciencia, Innovación y Universidades, Spain. X.A is granted with a fellowship (FI21-RH042199) from Agencia de Gestió d’Ajuts Universitaris I de Recerca., Peer reviewed